

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Submission for OMB Review; Comment Request**

*Title:* State Plan for Child Support Under Title IV–D of the Social Security Act (OCSE–100 and OCSE–21–U4).

*OMB No.:* 0970–0017.

*Description:* The State plan serves as a contract between the Office of Child

Support Enforcement (OCSE) and State IV–D agencies in outlining the activities the State will perform as required by law in order for States to receive Federal funds for child support enforcement. The information collected on the State plan pages is necessary to enable OCSE to determine whether each State has a IV–D State plan that meets the requirements in title IV–D of the Social Security Act (the Act) and implementing regulations. The State plan preprint gives each State a convenient method for developing a

statement to be submitted to OCSE for approval describing the nature and scope of its program and giving assurances that the program will be administered in conformity with the requirements in title IV–D of the Act and the implementing regulations at 45 CFR chapter III. Once received, the Federal office will review the State plan to ensure its compliance with regulations.

*Respondents:* State IV–D Agencies.

*Annual Burden Estimates:*

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
State Plan (OCSE–100) .....	54	6	.5	162
State Plan Transmittal (OCSE–21–U4) .....	54	6	.25	81
Estimated Total Annual Burden Hours: .....				243

*Additional Information:*

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All Requests should be identified by the title of the information collection. E-mail address: [grjohnson@acf.hhs.gov](mailto:grjohnson@acf.hhs.gov).

**OMB Comment**

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Attn: Desk Officer for ACF, e-mail address: [Katherine\\_T.\\_Astrich@omb.eop.gov](mailto:Katherine_T._Astrich@omb.eop.gov).

Dated: September 2, 2004.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 04–20372 Filed 9–8–04; 8:45 am]

**BILLING CODE 4184–01–M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Request for Nominations for Nonvoting Members Representing Industry Interests on Public Advisory Panels or Committees**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations for nonvoting industry representatives to serve on public advisory committees under the purview of the Center for Biologics Evaluation and Research (CBER).

**DATES:** Industry organizations interested in participating in the selection of a nonvoting member to represent industry for vacancies listed in this notice must send a letter to FDA by October 12, 2004, stating their interest in one or more committees.

Concurrently, nomination materials for prospective candidates should be sent to FDA by October 12, 2004. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative.

**ADDRESSES:** All letters of interest and nominations should be sent to the contact person listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

**FOR FURTHER INFORMATION CONTACT:** Gail Dapolito, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20857–1448, 301–827–0314, e-mail: [dpolito@cber.fda.gov](mailto:dpolito@cber.fda.gov).

**SUPPLEMENTARY INFORMATION:** Section 120 of the FDA Modernization Act of (FDAMA) of 1997 (21 U.S.C. 355) requires that FDA advisory committees include representatives from the biologics manufacturing industries. The agency intends to add nonvoting industry representatives to all its advisory committees identified in section I of this document.

**I. Functions**

*Advisory Committees Under the Purview of CBER*

*A. Allergenic Products Advisory Committee*

The committee reviews and evaluates available data concerning the safety, effectiveness, and adequacy of labeling of marketed and investigational allergenic biological products or materials that are administered to humans for the diagnosis, prevention, or treatment of allergies and allergic diseases.

*B. Blood Products Advisory Committee*

The committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood and products derived from blood and serum or biotechnology which are intended for use in the diagnosis,